Study to Determine Safety and Dosage of OPTISON in Pediatric Participants

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

39 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-12-01

Study Completion Date

2023-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study to determine the safety and appropriate dosage of OPTISON in pediatric participants since OPTISON has been tested in adult participants only during the clinical development

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Utility of Advanced Ultrasound Otoscope In The Diagnosis of AOM

NCT06429709

Otitis Media Recurrent Middle Ear Infection Ear Infection

ACTIVE_NOT_RECRUITING

Dexamethasone vs. Placebo in Children and Youth Hospitalized for Orbital Cellulitis

NCT07345819

Orbital Cellulitis

NOT_YET_RECRUITING NA

Evaluation of Safety and Efficacy of Lumason in Pediatric Echocardiography

NCT02282163

Heart Disease

TERMINATED PHASE3

Digital Otoscopy Versus Standard Otoscopy on the Diagnosis and Treatment of Otitis Media in Young Children

NCT07328555

Otitis Media Antimicrobial Stewardship

NOT_YET_RECRUITING NA

Contrast-enhanced MRI in Children 2 Months to <2 Years

NCT00937391

Magnetic Resonance Imaging

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Transthoracic Echocardiography Suspected or Known Structural or Functional Cardiac Abnormality

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Body Weight Group <=40 kg: OPTISON

Participants with body weight greater than or equal to (\>=) 20 to less than or equal to (\<=) 28 kilograms (kg) received OPTISON 0.1 milliliter (mL; dose level 1) or 0.2 mL (dose level 2); and participants with body weight greater than (\>) 28 to \<=40 kg received OPTISON 0.2 mL (dose level 1) or 0.3 mL (dose level 2) intravenous (IV) injection, 10 minutes apart on Day 1. The maximum allowed cumulative dose for body weight \>=20 to \<=28 kg and \>28 to \<=40 kg was 1.0 mL and 1.5 mL per dose level, respectively.

The treated subjects received both dose levels. Per protocol, up to 3 injections per dose level were allowed for acquiring different imaging views. A maximum of 2 injections was recorded in the treated population.

Group Type EXPERIMENTAL

Optison

Intervention Type DRUG

Optison is administered intravenously

Body Weight Group >40 kg: OPTISON

Participants with body weight \>40 kg received OPTISON 0.2 (dose level 1) or 0.4 mL (dose level 2) IV injection, 10 minutes apart on Day 1. The maximum allowed cumulative dose was 1.8 mL per dose level.

The treated subjects received both dose levels. Per protocol, up to 3 injections per dose level were allowed for acquiring different imaging views. A maximum of 2 injections was recorded in the treated population.

Group Type EXPERIMENTAL

Optison

Intervention Type DRUG

Optison is administered intravenously

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Optison

Optison is administered intravenously

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Perflutren Microspheres Injectable Suspension, USP

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The participant was between ≥9 and \<18 years of age and weighs ≥20 kg.
* The participant was clinically indicated to undergo a transthoracic echocardiogram.
* The participant had a suboptimal non-contrast echocardiogram defined as ≥2 contiguous segments in any given view that cannot be visualized.
* The participant was able to comply with study procedures.
* A parent or legal guardian of the participant had signed and dated an informed consent form.
* Post-menarchal female participants must have had a negative urine pregnancy test at screening and at pre-dose on the day of OPTISON administration.
* Post-menarchal female participants must have been practicing abstinence, or be using an effective form of birth control (e.g., intrauterine device, oral contraceptives, contraceptive implants or injections, diaphragm with spermicide, cervical cap, or consort use of condom) for at least 30 days before being enrolled in the study

Exclusion Criteria

* The participant was previously enrolled in this study.
* The participant received an investigational medicinal product within 30 days before or is scheduled to receive one from time of entry into this study until completion of the follow-up period proposed for this study.
* The participant had a known or suspected hypersensitivity to any of the components of OPTISON, blood, blood products, or albumin.
* The participant had pulmonary hypertension or unstable cardiopulmonary conditions.
* The participant had severe liver disease based on medical history.
* The participant had a recent (\<6 months) neurological event.
* The participant presented any clinically active, serious, life-threatening disease, with a life expectancy of less than 1 month or where study participation may compromise the management of the participant or other reason that in the judgment of the investigator makes the participant unsuitable for participation in the study.
* The participant was a pregnant or lactating female, or was a female of childbearing potential not using an acceptable form of birth control (negative urine pregnancy test was also required).

Minimum Eligible Age

9 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No